CMS Increases Outpatient Payment for Barostim Procedure
03 Novembre 2023 - 1:00PM
CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical
device company, announced today that Centers for Medicare and
Medicaid Services (CMS) has reassigned the Barostim implant
procedure for procedures performed in the outpatient setting as
part of the 2024 Medicare Hospital Outpatient Prospective Payment
System (OPPS) final rule.
In the 2024 OPPS final rule, Barostim was reassigned to New
Technology APC 1580, which carries an average payment amount of
$45,000. The new payment takes effect January 1, 2024. In 2023,
Barostim was assigned to APC 5465, which carries an average payment
amount of $29,000, with a Transitional Pass-Through Payment set to
expire on December 31, 2023.
“We sincerely appreciate the consideration taken by CMS of the
resource requirements associated with the Barostim implant
procedure. We believe that reassignment to APC 1580 will facilitate
increased access to the therapy for Medicare patients with heart
failure by offering facilities sufficient reimbursement for the
procedure,” said Nadim Yared, President and CEO of CVRx. “We are
grateful for the support of the cardiology physician community in
sharing their positive Barostim patient experience.”
About CVRx, Inc.CVRx is focused on the
development and commercialization of the Barostim™ System, the
first medical technology approved by FDA that uses neuromodulation
to improve the symptoms of heart failure. Barostim is an
implantable device that delivers electrical pulses to baroreceptors
located in the wall of the carotid artery. Baroreceptors activate
the body’s baroreflex, which in turn triggers an autonomic response
to the heart. The therapy is designed to restore balance to the
autonomic nervous system and thereby reduce the symptoms of heart
failure. Barostim received the FDA Breakthrough Device designation
and is FDA-approved for use in heart failure patients in the U.S.
It has also received the CE Mark for heart failure and resistant
hypertension in the European Economic Area. To learn more about
Barostim, visit www.cvrx.com.
Media Contact:Laura O’NeillFinn
Partners402-499-8203laura.oneill@finnpartners.com
Investor Contact:Mark Klausner or Mike
VallieICR Westwicke443.213.0501ir@cvrx.com
Grafico Azioni CVRx (NASDAQ:CVRX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni CVRx (NASDAQ:CVRX)
Storico
Da Mag 2023 a Mag 2024